Tags

Type your tag names separated by a space and hit enter

Practical aspects in the management of statin-associated muscle symptoms (SAMS).
Atheroscler Suppl. 2017 Apr; 26:45-55.AS

Abstract

BACKGROUND AND AIMS

Statin-associated muscle symptoms (SAMS) frequently cause statin non-adherence, switching and discontinuation, contributing to adverse cardiovascular (CV) outcomes. Therefore, the management of SAMS is key in the effective treatment of patients with cardiovascular disease (CVD), through achievement of maximum-tolerated statin dosing and other practical aspects. The aim of this article is to provide practical, focused advice for healthcare professionals on the management of patients with SAMS.

METHODS

An expert working group combined current evidence, published guidelines and experiences surrounding a number of topics concerning SAMS to provide recommendations on how to best assess and manage this condition and reach the highest tolerated dose of statin for each individual patient.

RESULTS

The group collaborated to provide guidance on definitions in the SAMS field, psychological issues, re-challenging and switching treatments, as well as interpretation of current guidelines and optimal treatment of SAMS in different patient populations. An algorithm was developed to guide the management of patients with SAMS. In addition, the expert working group considered some of the more complex scenarios in a series of frequently asked questions and suggested answers.

CONCLUSIONS

The expert working group gave recommendations for healthcare professionals on the management of SAMS but highlighted the importance of tailoring the treatment approach to each individual patient. Evidence supporting the role of nutraceuticals and complementary therapies, such as vitamin D, was lacking, however the majority of the group favoured combination therapy with ezetimibe and the addition of PCSK9 inhibitors in high-risk patients.

Authors+Show Affiliations

Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Center, Homburg, Germany. Electronic address: Ulrich.Laufs@uniklinikum-saarland.de.First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany.Department of Pharmacological and Biomolecular Sciences, University of Milan, and IRCCS Multimedica, Milan, Italy.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28434484

Citation

Laufs, Ulrich, et al. "Practical Aspects in the Management of Statin-associated Muscle Symptoms (SAMS)." Atherosclerosis. Supplements, vol. 26, 2017, pp. 45-55.
Laufs U, Filipiak KJ, Gouni-Berthold I, et al. Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler Suppl. 2017;26:45-55.
Laufs, U., Filipiak, K. J., Gouni-Berthold, I., & Catapano, A. L. (2017). Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atherosclerosis. Supplements, 26, 45-55. https://doi.org/10.1016/S1567-5688(17)30024-7
Laufs U, et al. Practical Aspects in the Management of Statin-associated Muscle Symptoms (SAMS). Atheroscler Suppl. 2017;26:45-55. PubMed PMID: 28434484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Practical aspects in the management of statin-associated muscle symptoms (SAMS). AU - Laufs,Ulrich, AU - Filipiak,Krysztof J, AU - Gouni-Berthold,Ioanna, AU - Catapano,Alberico L, AU - ,, PY - 2017/4/25/entrez PY - 2017/4/25/pubmed PY - 2018/3/15/medline KW - Cardiovascular disease KW - Cholesterol KW - Lipids KW - Muscle symptoms KW - Myalgia KW - Myopathy KW - Statin KW - Statin intolerance SP - 45 EP - 55 JF - Atherosclerosis. Supplements JO - Atheroscler Suppl VL - 26 N2 - BACKGROUND AND AIMS: Statin-associated muscle symptoms (SAMS) frequently cause statin non-adherence, switching and discontinuation, contributing to adverse cardiovascular (CV) outcomes. Therefore, the management of SAMS is key in the effective treatment of patients with cardiovascular disease (CVD), through achievement of maximum-tolerated statin dosing and other practical aspects. The aim of this article is to provide practical, focused advice for healthcare professionals on the management of patients with SAMS. METHODS: An expert working group combined current evidence, published guidelines and experiences surrounding a number of topics concerning SAMS to provide recommendations on how to best assess and manage this condition and reach the highest tolerated dose of statin for each individual patient. RESULTS: The group collaborated to provide guidance on definitions in the SAMS field, psychological issues, re-challenging and switching treatments, as well as interpretation of current guidelines and optimal treatment of SAMS in different patient populations. An algorithm was developed to guide the management of patients with SAMS. In addition, the expert working group considered some of the more complex scenarios in a series of frequently asked questions and suggested answers. CONCLUSIONS: The expert working group gave recommendations for healthcare professionals on the management of SAMS but highlighted the importance of tailoring the treatment approach to each individual patient. Evidence supporting the role of nutraceuticals and complementary therapies, such as vitamin D, was lacking, however the majority of the group favoured combination therapy with ezetimibe and the addition of PCSK9 inhibitors in high-risk patients. SN - 1878-5050 UR - https://www.unboundmedicine.com/medline/citation/28434484/Practical_aspects_in_the_management_of_statin_associated_muscle_symptoms__SAMS__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5688(17)30024-7 DB - PRIME DP - Unbound Medicine ER -